Status:
COMPLETED
Impact of Mortality Salience on Treatment Decisions
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborating Sponsors:
UHN - Princess Margaret Cancer Centre, Toronto, Canada
Conditions:
Urological Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if mortality salience has an impact on treatment decisions in urologists and patients with urological cancer. The main questions it aims to answer are: Doe...
Detailed Description
Background: Harmful overtreatment is a major problem in oncology. Unconscious fear of death (mortality salience) could increase the likelihood of a physician or patient decision in favor of aggressive...
Eligibility Criteria
Inclusion
- Study 1) Urologists
- sufficient cognitive ability
- German language skills
Exclusion
- none
- Study 2) Patients
- Inclusion Criteria:
- urological cancer (ICD-10: C60, C61, C62, C63, C64, C65, C66, C67, C68)
- age at least 18 years
- German language skills
- sufficient cognitive ability
- capacity to consent
Key Trial Info
Start Date :
September 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2025
Estimated Enrollment :
746 Patients enrolled
Trial Details
Trial ID
NCT06545188
Start Date
September 16 2024
End Date
November 8 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Düsseldorf, Department of Urology
Düsseldorf, Germany, 40225